| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 19 | 2024 | 24 | 3.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 30 | 2023 | 36 | 3.090 |
Why?
|
| Vasculitis | 22 | 2022 | 51 | 2.440 |
Why?
|
| Immunosuppressive Agents | 18 | 2024 | 304 | 2.280 |
Why?
|
| Glomerulonephritis | 14 | 2024 | 30 | 2.230 |
Why?
|
| Kidney Failure, Chronic | 20 | 2022 | 193 | 1.840 |
Why?
|
| Peroxidase | 14 | 2024 | 70 | 1.640 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 8 | 2023 | 11 | 1.530 |
Why?
|
| Cyclophosphamide | 12 | 2023 | 71 | 1.270 |
Why?
|
| Lupus Nephritis | 7 | 2022 | 33 | 1.090 |
Why?
|
| Kidney | 13 | 2023 | 397 | 1.070 |
Why?
|
| Myeloblastin | 12 | 2023 | 14 | 1.060 |
Why?
|
| Kidney Diseases | 5 | 2021 | 160 | 0.900 |
Why?
|
| Nephrotic Syndrome | 3 | 2021 | 7 | 0.880 |
Why?
|
| Kidney Transplantation | 9 | 2023 | 268 | 0.880 |
Why?
|
| Glomerulonephritis, Membranous | 7 | 2023 | 14 | 0.790 |
Why?
|
| Granulomatosis with Polyangiitis | 6 | 2023 | 14 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2024 | 118 | 0.680 |
Why?
|
| Glucocorticoids | 6 | 2016 | 172 | 0.660 |
Why?
|
| Middle Aged | 62 | 2024 | 16542 | 0.610 |
Why?
|
| Adult | 57 | 2024 | 15972 | 0.580 |
Why?
|
| Churg-Strauss Syndrome | 4 | 2023 | 15 | 0.560 |
Why?
|
| Aged | 50 | 2023 | 13596 | 0.530 |
Why?
|
| Humans | 96 | 2024 | 60081 | 0.530 |
Why?
|
| Male | 69 | 2024 | 27951 | 0.520 |
Why?
|
| Plasmapheresis | 2 | 2013 | 18 | 0.500 |
Why?
|
| Female | 68 | 2024 | 31226 | 0.480 |
Why?
|
| Risk Factors | 28 | 2024 | 5090 | 0.470 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 35 | 0.450 |
Why?
|
| Apolipoprotein L1 | 3 | 2023 | 6 | 0.450 |
Why?
|
| Albuminuria | 3 | 2012 | 24 | 0.450 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 116 | 0.440 |
Why?
|
| Silicon Dioxide | 2 | 2007 | 59 | 0.440 |
Why?
|
| Nephrosis, Lipoid | 4 | 2020 | 6 | 0.440 |
Why?
|
| Spouses | 2 | 2015 | 38 | 0.440 |
Why?
|
| Prednisone | 1 | 2013 | 80 | 0.440 |
Why?
|
| Adolescent | 22 | 2024 | 5944 | 0.430 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 152 | 0.420 |
Why?
|
| Renal Dialysis | 9 | 2016 | 186 | 0.400 |
Why?
|
| Recurrence | 12 | 2023 | 600 | 0.380 |
Why?
|
| Remission Induction | 8 | 2016 | 139 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 59 | 0.360 |
Why?
|
| Occupational Diseases | 2 | 2015 | 266 | 0.340 |
Why?
|
| Mycophenolic Acid | 5 | 2014 | 32 | 0.340 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 157 | 0.330 |
Why?
|
| Occupational Exposure | 2 | 2015 | 307 | 0.320 |
Why?
|
| Young Adult | 16 | 2024 | 4398 | 0.320 |
Why?
|
| Autoantigens | 6 | 2023 | 125 | 0.320 |
Why?
|
| Time Factors | 14 | 2020 | 3621 | 0.320 |
Why?
|
| North Carolina | 8 | 2016 | 67 | 0.310 |
Why?
|
| Retrospective Studies | 16 | 2024 | 6147 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 95 | 0.310 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 538 | 0.300 |
Why?
|
| Child | 13 | 2024 | 4313 | 0.300 |
Why?
|
| Calcineurin Inhibitors | 4 | 2016 | 22 | 0.290 |
Why?
|
| Autoimmune Diseases | 6 | 2024 | 223 | 0.290 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2024 | 201 | 0.290 |
Why?
|
| Prescription Drugs | 2 | 2022 | 50 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2021 | 38 | 0.280 |
Why?
|
| Glomerulonephritis, IGA | 3 | 2020 | 7 | 0.270 |
Why?
|
| Prognosis | 9 | 2022 | 1591 | 0.270 |
Why?
|
| Case-Control Studies | 11 | 2019 | 1064 | 0.270 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 160 | 0.270 |
Why?
|
| Epitopes | 3 | 2019 | 294 | 0.270 |
Why?
|
| Disease Progression | 6 | 2023 | 1053 | 0.260 |
Why?
|
| Quality of Life | 3 | 2012 | 1140 | 0.260 |
Why?
|
| Biopsy | 7 | 2022 | 375 | 0.260 |
Why?
|
| Communicable Diseases | 2 | 2020 | 83 | 0.260 |
Why?
|
| Kidney Glomerulus | 3 | 2017 | 20 | 0.260 |
Why?
|
| Hypertension | 4 | 2023 | 603 | 0.240 |
Why?
|
| B-Lymphocytes | 3 | 2015 | 552 | 0.240 |
Why?
|
| Child, Preschool | 6 | 2024 | 1839 | 0.240 |
Why?
|
| Pesticides | 2 | 2015 | 55 | 0.230 |
Why?
|
| Neutrophils | 3 | 2020 | 352 | 0.230 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2024 | 9 | 0.230 |
Why?
|
| Genotype | 8 | 2023 | 628 | 0.230 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2024 | 18 | 0.230 |
Why?
|
| CD5 Antigens | 2 | 2015 | 18 | 0.230 |
Why?
|
| Incidence | 6 | 2020 | 1267 | 0.230 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2014 | 3 | 0.220 |
Why?
|
| Autoantibodies | 5 | 2024 | 175 | 0.220 |
Why?
|
| Autoimmunity | 2 | 2024 | 222 | 0.220 |
Why?
|
| Aged, 80 and over | 14 | 2013 | 5200 | 0.220 |
Why?
|
| Infertility | 1 | 2024 | 33 | 0.220 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 35 | 0.210 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 345 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 457 | 0.210 |
Why?
|
| Leukocytes | 2 | 2014 | 95 | 0.210 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 45 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2023 | 2480 | 0.200 |
Why?
|
| Proteinuria | 5 | 2022 | 37 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 679 | 0.200 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 7 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2012 | 743 | 0.200 |
Why?
|
| Anticholesteremic Agents | 3 | 2007 | 34 | 0.190 |
Why?
|
| Smoking | 1 | 2007 | 837 | 0.190 |
Why?
|
| Podocytes | 1 | 2021 | 8 | 0.180 |
Why?
|
| Venous Thromboembolism | 2 | 2013 | 142 | 0.180 |
Why?
|
| Prevalence | 5 | 2024 | 1299 | 0.180 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 1239 | 0.180 |
Why?
|
| United States | 11 | 2023 | 7622 | 0.180 |
Why?
|
| Obesity | 2 | 2024 | 1191 | 0.170 |
Why?
|
| Survival Rate | 4 | 2015 | 793 | 0.170 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2019 | 5 | 0.170 |
Why?
|
| Complement C5a | 1 | 2019 | 5 | 0.170 |
Why?
|
| Complement C3a | 1 | 2019 | 7 | 0.170 |
Why?
|
| Complement Factor B | 1 | 2019 | 11 | 0.170 |
Why?
|
| Systemic Vasculitis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Mice, Knockout | 1 | 2024 | 1995 | 0.160 |
Why?
|
| Medication Adherence | 2 | 2013 | 245 | 0.160 |
Why?
|
| Rituximab | 5 | 2023 | 82 | 0.150 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 94 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2074 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2024 | 3133 | 0.150 |
Why?
|
| Thyroid Diseases | 2 | 2007 | 26 | 0.140 |
Why?
|
| Treatment Outcome | 9 | 2016 | 5266 | 0.140 |
Why?
|
| Surveys and Questionnaires | 9 | 2015 | 2615 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2014 | 1465 | 0.140 |
Why?
|
| Heptanoic Acids | 2 | 2007 | 21 | 0.130 |
Why?
|
| Infant | 4 | 2017 | 1522 | 0.130 |
Why?
|
| Alleles | 3 | 2014 | 417 | 0.130 |
Why?
|
| Hospitalization | 2 | 2020 | 1304 | 0.130 |
Why?
|
| Pyrroles | 2 | 2007 | 50 | 0.130 |
Why?
|
| Caregivers | 1 | 2019 | 232 | 0.130 |
Why?
|
| Hematinics | 2 | 2014 | 10 | 0.130 |
Why?
|
| Sex Factors | 5 | 2011 | 971 | 0.130 |
Why?
|
| Cost of Illness | 2 | 2019 | 157 | 0.130 |
Why?
|
| Ethylene Glycol | 1 | 2015 | 7 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 677 | 0.130 |
Why?
|
| Antibody Specificity | 2 | 2013 | 100 | 0.130 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2015 | 29 | 0.130 |
Why?
|
| Farmers | 1 | 2015 | 18 | 0.130 |
Why?
|
| Poisoning | 1 | 2015 | 29 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 240 | 0.120 |
Why?
|
| Agriculture | 1 | 2015 | 29 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 142 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 1037 | 0.120 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 168 | 0.120 |
Why?
|
| Serum Albumin | 5 | 2016 | 40 | 0.120 |
Why?
|
| Creatinine | 5 | 2022 | 123 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 1527 | 0.120 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 63 | 0.120 |
Why?
|
| Risk Assessment | 6 | 2020 | 1936 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 275 | 0.120 |
Why?
|
| HLA-DR Antigens | 2 | 2011 | 27 | 0.110 |
Why?
|
| Sickle Cell Trait | 1 | 2014 | 7 | 0.110 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 161 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 212 | 0.110 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 31 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 8 | 0.110 |
Why?
|
| Patient Selection | 2 | 2013 | 453 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 831 | 0.110 |
Why?
|
| Neoplasms | 1 | 2023 | 1262 | 0.110 |
Why?
|
| Apolipoproteins | 2 | 2023 | 16 | 0.110 |
Why?
|
| Histones | 1 | 2016 | 465 | 0.100 |
Why?
|
| Information Dissemination | 2 | 2011 | 119 | 0.100 |
Why?
|
| Rural Population | 2 | 2015 | 193 | 0.100 |
Why?
|
| Glucuronides | 2 | 2009 | 6 | 0.100 |
Why?
|
| Health Education | 2 | 2011 | 184 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 214 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1038 | 0.100 |
Why?
|
| Health Transition | 1 | 2012 | 5 | 0.100 |
Why?
|
| Social Participation | 1 | 2012 | 16 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2012 | 105 | 0.100 |
Why?
|
| Friends | 1 | 2012 | 29 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2013 | 171 | 0.100 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2011 | 14 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2011 | 34 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 183 | 0.100 |
Why?
|
| Neutrophil Activation | 2 | 2020 | 24 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2012 | 147 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2008 | 189 | 0.090 |
Why?
|
| Chronic Disease | 3 | 2009 | 744 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 928 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2013 | 353 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 87 | 0.090 |
Why?
|
| Internet | 2 | 2012 | 465 | 0.090 |
Why?
|
| Graft Survival | 2 | 2021 | 280 | 0.090 |
Why?
|
| Urinary Tract Infections | 1 | 2011 | 79 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2011 | 37 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1471 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 2360 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2010 | 11 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 106 | 0.090 |
Why?
|
| Pilot Projects | 5 | 2014 | 930 | 0.090 |
Why?
|
| Gene Expression | 3 | 2020 | 808 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 66 | 0.090 |
Why?
|
| Health Surveys | 2 | 2012 | 311 | 0.090 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 68 | 0.080 |
Why?
|
| Losartan | 1 | 2009 | 18 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2022 | 210 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 569 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2013 | 489 | 0.080 |
Why?
|
| Registries | 4 | 2016 | 811 | 0.080 |
Why?
|
| Perception | 1 | 2010 | 179 | 0.080 |
Why?
|
| Plasminogen | 1 | 2008 | 7 | 0.080 |
Why?
|
| Steroids | 2 | 2013 | 55 | 0.080 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 9 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2009 | 199 | 0.080 |
Why?
|
| Medicare | 2 | 2023 | 603 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2016 | 558 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 105 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2024 | 306 | 0.080 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 20 | 0.070 |
Why?
|
| Phenotype | 4 | 2015 | 1145 | 0.070 |
Why?
|
| Health Status | 1 | 2011 | 451 | 0.070 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 18 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 173 | 0.070 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2008 | 49 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2013 | 272 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2012 | 483 | 0.070 |
Why?
|
| Lipoproteins | 1 | 2007 | 82 | 0.070 |
Why?
|
| North America | 2 | 2020 | 115 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 26 | 0.070 |
Why?
|
| Cotinine | 1 | 2007 | 18 | 0.070 |
Why?
|
| Spleen | 2 | 2024 | 486 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2016 | 406 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2007 | 58 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2009 | 522 | 0.070 |
Why?
|
| Organ Transplantation | 1 | 2007 | 52 | 0.070 |
Why?
|
| Serine Endopeptidases | 2 | 2004 | 82 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 319 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2015 | 850 | 0.060 |
Why?
|
| Cholestyramine Resin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2005 | 6 | 0.060 |
Why?
|
| Anemia | 1 | 2007 | 118 | 0.060 |
Why?
|
| Iowa | 2 | 2015 | 20 | 0.060 |
Why?
|
| Health Promotion | 1 | 2010 | 490 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2008 | 282 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2005 | 39 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2507 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 57 | 0.060 |
Why?
|
| Prodrugs | 1 | 2005 | 32 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 249 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2007 | 306 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2007 | 334 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 251 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 50 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2024 | 892 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2024 | 148 | 0.060 |
Why?
|
| Nicaragua | 1 | 2023 | 16 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 292 | 0.060 |
Why?
|
| Mice | 4 | 2024 | 10317 | 0.060 |
Why?
|
| Transplant Recipients | 1 | 2023 | 31 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 970 | 0.050 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 70 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2019 | 1572 | 0.050 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2002 | 28 | 0.050 |
Why?
|
| Living Donors | 1 | 2003 | 65 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 436 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 105 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 621 | 0.050 |
Why?
|
| HLA-DP beta-Chains | 1 | 2022 | 2 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1542 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2023 | 137 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 344 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2003 | 134 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2003 | 166 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 180 | 0.050 |
Why?
|
| Animals | 5 | 2024 | 19739 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2013 | 638 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2002 | 309 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2012 | 677 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 45 | 0.050 |
Why?
|
| Dust | 1 | 2001 | 39 | 0.050 |
Why?
|
| Drug Information Services | 2 | 2011 | 5 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2012 | 129 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2012 | 125 | 0.040 |
Why?
|
| Self Care | 2 | 2013 | 212 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 423 | 0.040 |
Why?
|
| Nephrology | 1 | 2000 | 15 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 1565 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 183 | 0.040 |
Why?
|
| HLA-DRB1 Chains | 2 | 2011 | 12 | 0.040 |
Why?
|
| Complement C4 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Biomarkers | 3 | 2013 | 1214 | 0.040 |
Why?
|
| Properdin | 1 | 2019 | 13 | 0.040 |
Why?
|
| Focus Groups | 2 | 2012 | 294 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 477 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2000 | 149 | 0.040 |
Why?
|
| Life Style | 2 | 2012 | 330 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 2095 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 661 | 0.040 |
Why?
|
| Social Support | 2 | 2012 | 366 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1262 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1142 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 713 | 0.040 |
Why?
|
| Antibodies | 2 | 2008 | 176 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 280 | 0.040 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2017 | 5 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2017 | 24 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1224 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1175 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3215 | 0.030 |
Why?
|
| Acylation | 1 | 2016 | 15 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 604 | 0.030 |
Why?
|
| Length of Stay | 1 | 2000 | 782 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 2361 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 127 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 44 | 0.030 |
Why?
|
| Poison Control Centers | 1 | 2015 | 6 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 2015 | 8 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 2015 | 14 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 32 | 0.030 |
Why?
|
| Acidosis | 1 | 2015 | 26 | 0.030 |
Why?
|
| Herbicides | 1 | 2015 | 18 | 0.030 |
Why?
|
| Occupations | 1 | 2015 | 52 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 1100 | 0.030 |
Why?
|
| Cholesterol | 2 | 2007 | 255 | 0.030 |
Why?
|
| Suicide, Attempted | 1 | 2015 | 103 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2014 | 11 | 0.030 |
Why?
|
| Hypoalbuminemia | 1 | 2013 | 6 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 383 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 37 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 361 | 0.030 |
Why?
|
| Decision Trees | 1 | 2013 | 51 | 0.030 |
Why?
|
| Uncertainty | 1 | 2013 | 33 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2013 | 73 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 450 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 90 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 806 | 0.030 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 353 | 0.030 |
Why?
|
| Systems Biology | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 4 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 118 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 195 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 25 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 105 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 70 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 185 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 120 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 255 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 77 | 0.020 |
Why?
|
| Feedback | 1 | 2012 | 87 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 104 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 237 | 0.020 |
Why?
|
| Online Systems | 1 | 2011 | 21 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 233 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 220 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 281 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 288 | 0.020 |
Why?
|
| Comprehension | 1 | 2012 | 130 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 391 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 53 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 258 | 0.020 |
Why?
|
| Disease Management | 1 | 2012 | 222 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 337 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 359 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 495 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 845 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Information Seeking Behavior | 1 | 2009 | 36 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 102 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 191 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 309 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 26 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1965 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 585 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 208 | 0.020 |
Why?
|
| France | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cell Count | 1 | 2008 | 129 | 0.020 |
Why?
|
| snRNP Core Proteins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2008 | 24 | 0.020 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2008 | 20 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 457 | 0.020 |
Why?
|
| Glycosuria | 1 | 2007 | 3 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2007 | 9 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2007 | 19 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2008 | 34 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2007 | 22 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 1908 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2007 | 31 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2008 | 49 | 0.020 |
Why?
|
| Hematuria | 1 | 2007 | 20 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 232 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2008 | 174 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2007 | 4 | 0.020 |
Why?
|
| Decision Making | 1 | 2011 | 394 | 0.020 |
Why?
|
| Ferrous Compounds | 1 | 2007 | 12 | 0.020 |
Why?
|
| Kidney Tubules, Distal | 1 | 2007 | 4 | 0.020 |
Why?
|
| Communication | 1 | 2012 | 558 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 11 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2007 | 33 | 0.020 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2007 | 18 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2008 | 98 | 0.020 |
Why?
|
| Professional Role | 1 | 2007 | 39 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 524 | 0.020 |
Why?
|
| Iron | 1 | 2007 | 139 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 774 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 395 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2007 | 125 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 450 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2007 | 133 | 0.020 |
Why?
|
| Program Development | 1 | 2007 | 211 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2005 | 36 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 868 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2005 | 29 | 0.020 |
Why?
|
| Polysaccharides | 1 | 2007 | 147 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 742 | 0.020 |
Why?
|
| Pharmacists | 1 | 2007 | 126 | 0.020 |
Why?
|
| Physicians | 1 | 2011 | 442 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 546 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2005 | 54 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 852 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2007 | 492 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 344 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 2004 | 50 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2003 | 31 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2003 | 44 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 684 | 0.010 |
Why?
|
| Triglycerides | 1 | 2005 | 242 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2005 | 531 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 853 | 0.010 |
Why?
|
| Particle Size | 1 | 2005 | 400 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 12 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1042 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2002 | 34 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2003 | 252 | 0.010 |
Why?
|
| Superoxides | 1 | 2002 | 69 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 44 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 448 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 2892 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 149 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 471 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 189 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 1111 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 278 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 661 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 911 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 443 | 0.010 |
Why?
|
| Insulin | 1 | 2002 | 692 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 847 | 0.010 |
Why?
|